Țară: Israel
Limbă: engleză
Sursă: Ministry of Health
SEVELAMER CARBONATE ANHYDROUS
TARO INTERNATIONAL LTD, ISRAEL
V03AE02
FILM COATED TABLETS
SEVELAMER CARBONATE ANHYDROUS 800 MG
PER OS
Required
SYNTHON B.V., NETHERLANDS
SEVELAMER
For the control of hyperphosphataemia in adult patients receiving haemodialysis or peritoneal dialysis.Also indicated for the control of hyperphosphataemia in adult patients with chronic kidney disease not on dialysis with serum phosphorus ≥ 1.78 mmol/l.Should be used within the context of a multiple therapeutic approach, which could include calcium supplement, 1,25-dihydroxy Vitamin D3 or one of its analogues to control the development of renal bone disease.
2021-12-31
Page 1 of 6 PATIENT LEAFLET IN ACCORDANCE WITH THE PHARMACISTS' REGULATIONS (PREPARATIONS) - 1986 This medicine is dispensed with a doctor’s prescription only SEVELAMER TARO 800 MG TABLETS ACTIVE INGREDIENT: Each film-coated tablet contains: sevelamer carbonate anhydrous 800 mg SEVELAMER TARO 2.4 G POWDER FOR ORAL SUSPENSION ACTIVE INGREDIENT: Each sachet of powder contains: sevelamer carbonate anhydrous 2.4 gram Inactive ingredients and allergens: See the section 'Important information about some of this medicine’s ingredients', and section 6 ‘Additional information’. READ THE ENTIRE LEAFLET CAREFULLY BEFORE YOU START USING THIS MEDICINE. This leaflet contains concise information about this medicine. Keep the leaflet. You may need to read it again. If you have any further questions, consult your doctor or pharmacist. This medicine has been prescribed to treat your illness. Do not pass it on to others. It may harm them, even if it seems to you that their illness is similar to yours. 1. WHAT IS THIS MEDICINE INTENDED FOR? This medicine is intended for: • Controlling high levels of phosphate in blood of adult patients who are on dialysis (hemodialysis or peritoneal dialysis). • Controlling high levels of phosphate in blood of adult patients with a chronic kidney disease who are not on dialysis, have a blood phosphorus level equal to or above 1.78 mmol/l. The medicine should be used with other treatments such as calcium supplements and vitamin D to prevent the development of bone disease due to kidney disease. THERAPEUTIC GROUP: phosphate binders. Sevelamer carbonate binds phosphate from food in the digestive tract and in this way reduces serum phosphorus levels in the blood. 2. BEFORE USING THIS MEDICINE DO NOT USE THIS MEDICINE IF: • You are sensitive (allergic) to the active ingredient sevelamer or to any of the other ingredients in this medicine (see section 6). • You have low blood phosphate levels (the doctor will check this for you). • You have a blockage in your bowel. Page 2 of 6 SPECIAL W Citiți documentul complet